CDA | Evidence Driven
CDA | Evidence Driven

nemolizumab

Details

Generic Name:
nemolizumab
Project Status:
Pending
Therapeutic Area:
Prurigo nodularis (PN)
Manufacturer:
Galderma Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0861-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​For the treatment of adult patients with moderate to severe prurigo nodularis (PN).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​For the treatment of prurigo nodularis (PN).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : November 21, 2024